Elana Gotkine
TUESDAY, Dec. 27, 2022 (HealthDay News) -- Direct oral anticoagulants (DOACs) are more effective and cost-effective than low-molecular-weight heparin for cancer-associated thrombosis…
Findings from a new study at the Marshall University Joan C. Edwards School of Medicine show that a thymidine phosphorylase (TYMP) inhibitor could help slow thrombosis in COVID-19 patients.
Expression of TYMP, the gene that plays an…
Cerebral venous thrombosis is a rare form of cerebral circulatory disorder that, unlike classic stroke, more often affects younger people. For unknown reasons, blood clots (thrombi) form in cerebral veins, obstructing blood flow and causing…
Researchers examined autopsy tissue samples of hearts from patients who died early in the COVID-19 pandemic. Frequent and extensive blood clots (thromboses) within heart vessels were found as anticipated, but the type of changes in the…
They found that at a total daily dose of 100 mg or more, milvexian resulted in better clot protection but no increase in bleeding compared with enoxaparin, the control drug. Milvexian was evaluated in daily doses ranging from 25 to 400…
For high-bleeding risk patients, a shorter duration of dual antiplatelet therapy (DAPT) appeared just as safe for those getting novel stent after acute myocardial infarction (MI) in…
SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress, being held…